目前,临床上对于慢性乙型病毒性肝炎抗病毒治疗的目的是抑制乙肝病毒(HBV)复制、减轻肝组织病变、改善肝功能、降低传染性、减轻或阻止肝硬化的发生、提高患者的生活质量[1],然而,临床实践表明,单用一种抗HBV的药物疗效往往不佳,因此,探讨联合应用抗HBV药物的效果已成为业内学者关注的重点。近年来,我院对收治的慢性乙肝轻中型患者在予保肝、利胆、抗炎、对症等基础治疗上,分别单独应用拉米夫定和拉米夫定与α-2b干扰素联合应用抗病毒治疗,并 At present, the clinical treatment of chronic hepatitis B virus antiviral therapy aims to inhibit the replication of hepatitis B virus (HBV), reduce liver disease, improve liver function, reduce infectious, reduce or prevent the occurrence of cirrhosis, improve patient’s life However, clinical practice shows that the curative effect of anti-HBV drugs alone is often poor. Therefore, it has become the focus of scholars in the industry to explore the effect of combining anti-HBV drugs. In recent years, our hospital on the treatment of chronic hepatitis B in patients with mild to moderate liver, gallbladder, anti-inflammatory, symptomatic and other basic treatment, respectively, lamivudine and lamivudine alone with interferon α-2b in combination Antiviral therapy, and